Related Experiment Video
Updated: May 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Epidemiological impact of mandatory vaccination against hepatitis B in Italian young adults
Marcello Campagna1, Andrea Siddu, Angelo Meloni
1Department of Public Health, University of Cagliari, Cagliari, Italy.
Insights
Hepatitis B virus (HBV) vaccination in Italy demonstrates long-term immunity for individuals vaccinated at birth or as adolescents. The national vaccination strategy effectively reduced HBV prevalence.
Area of Science:
- Hepatology
- Immunology
- Public Health
Background:
- Hepatitis B virus (HBV) infection is a significant global cause of acute and chronic liver disease.
- Italy implemented a mandatory HBV vaccination policy in 1991 for newborns and 12-year-olds, later discontinuing adolescent vaccination in 2004 while maintaining infant vaccination.
Purpose of the Study:
- To evaluate the seroprevalence of HBV markers in vaccinated individuals.
- To assess the long-term effectiveness of Italy's national HBV vaccination policy.
Main Methods:
- Serological assessment of HBV markers in 806 individuals vaccinated at birth or at 12 years of age.
- Analysis of anti-HBs, anti-HBc, and HBsAg prevalence to determine vaccination effectiveness and immunity.
Main Results:
- High overall prevalence of anti-HBs antibodies (90.32%), indicating sustained immunity.
- Low prevalence of active HBV infection (1.61% HBsAg positive).
- A small percentage showed mixed immunity markers (2.23% anti-HBs and anti-HBc positive) or were negative for all tested markers (5.83%).
Conclusions:
- HBV vaccination confers long-term immunity when administered at birth or to healthy adolescents.
- The national vaccination strategy in Italy has proven effective in controlling HBV infection.
Background:
Viral hepatitis caused by hepatitis B virus (HBV) is a leading cause of acute and chronic liver diseases worldwide.
Objectives:
In Italy, a mandatory vaccination policy was introduced in 1991 and was established for all newborns and 12-year-old individuals. In 2004, vaccination of 12-year old adolescents was discontinued, and that of infants was maintained.
Patients And Methods:
We evaluated the seroprevalence of HBV markers in 806 individuals, who were vaccinated at birth or at 12 years of age, to assess the effectiveness of the national policy against HBV.
Results:
The overall prevalence of anti-HBs antibodies was 90.32% (95% confidence interval [CI]: 88.28-92.36%); 2.23% (95% CI: 1.21-3.25%) of the subjects were positive for both antibodies to HBsAg (anti-HBs) and antibodies to hepatitis B core antigen (anti-HBc), whereas 5.83% (95% CI 4.21-7.45) of the subjects were negative for all markers tested. Further, 1.61% (95% CI: 0.74-2.48%) of the subjects were positive for hepatitis B surface antigen (HBsAg).
Conclusions:
Our data provide additional evidence that HBV vaccination can confer long-term immunity when performed at birth and when performed for healthy adolescents; moreover, the results show the effectiveness of the application of a national vaccination strategy.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Vaccinations
Bias in Epidemiological Studies
Vaccines
Infectious Diseases and Their Occurrence